Nexalin announces study on AD, DIFS published in Journal of Alzheimer’s Disease

Nexalin Technology (NXL) announced publication of a landmark study titled, “Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer’s Disease After Transcranial Alternating Current Stimulation, tACS,: A Resting-State Functional Magnetic Resonance Imaging Study” in the Journal of Alzheimer’s Disease. This study builds on recent findings from Nexalin’s Deep Intracranial Frequency Stimulation, DIFS, research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer’s disease, AD. This new research involved 46 patients, randomly assigned to receive either real DIFS or sham treatment for 30 one-hour sessions over a period of three weeks. Resting-state functional magnetic resonance imaging was used to track changes in brain activity, showing that Nexalin’s proprietary DIFS technology significantly alters neuronal activity in key regions of the brain, providing a non-pharmacological, safe treatment option for Alzheimer’s.